Psychiatry drugs

40 results

  • abilify

    (ARIPIPRAZOLE)
    Otsuka America Pharmaceutical, Inc.
    ABILIFY (aripiprazole) is indicated for the treatment of schizophrenia, acute manic and mixed episodes associated with Bipolar I Disorder, adjunctive treatment of major depressive disorder, irritability associated with autistic disorder, and treatment of Tourette's disorder.

  • abilify asimtufii

    (Aripiprazole)
    Otsuka America Pharmaceutical, Inc
    ABILIFY ASIMTUFII is indicated for the treatment of schizophrenia in adults and for maintenance monotherapy of bipolar I disorder in adults.

  • abilify maintena

    (aripiprazole)
    Otsuka America Pharmaceutical, Inc.
    ABILIFY MAINTENA (aripiprazole) is indicated for the treatment of schizophrenia and as maintenance monotherapy for bipolar I disorder in adults.

  • abilify mycite

    (ARIPIPRAZOLE)
    Otsuka America Pharmaceutical, Inc.
    ABILIFY MYCITE is indicated for treating adults with schizophrenia, bipolar I disorder (including both acute and maintenance phases), and as adjunctive therapy for Major Depressive Disorder. It features an Ingestible Event Marker (IEM) sensor to track medication ingestion.

  • addyi

    (flibanserin)
    Sprout Pharmaceuticals, Inc.
    ADDYI is indicated for treating premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) that causes significant distress and is not linked to medical/psychiatric conditions, relationship issues, or medication effects. It is not approved for postmenopausal women, men, or to enhance sexual performance.

  • aplenzin

    (bupropion hydrobromide)
    Bausch Health US, LLC
    APLENZIN (bupropion hydrobromide) is indicated for the treatment of major depressive disorder (MDD) and for the prevention of seasonal major depressive episodes in patients with seasonal affective disorder (SAD). Its efficacy has been demonstrated in various controlled clinical trials.

  • aristada

    (aripiprazole lauroxil)
    Alkermes, Inc.
    ARISTADA is indicated for the treatment of schizophrenia in adults.

  • azstarys

    (Serdexmethylphenidate and Dexmethylphenidate)
    Corium, LLC.
    AZSTARYS is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 years and older.

  • barhemsys

    (Amisulpride)
    Acacia Pharma Ltd
    BARHEMSYS® is indicated for adults to prevent and treat postoperative nausea and vomiting (PONV), either alone or in combination with a different class antiemetic, and for patients who have or have not received prior antiemetic prophylaxis.

  • belbuca

    (buprenorphine hydrochloride)
    BioDelivery Sciences International Inc
    BELBUCA is indicated for managing severe and persistent pain requiring long-term opioid treatment when other options are inadequate. It is not intended for as-needed use and should be reserved for patients unable to tolerate or achieve relief with non-opioid or immediate-release opioids due to risks of addiction and overdose.